EUVIMEDEUVIMED entdecken
Leserbrief

Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity

Dandan Weng iD, Pingping Zhang

Alimentary Pharmacology & Therapeutics · 03.10.2026

DOI: 10.1111/apt.71030 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 03.10.2026. Verfasst von Dandan Weng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Affiliated Yangming Hospital of Ningbo University, Yuyao, Zhejiang, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Infectious Diseases, Affiliated Yangming Hospital of Ningbo University, Yuyao, Zhejiang, China.

ORCID-Profile: Dandan Weng

Zitieren

APA

Weng, D., & Zhang, P. (2026). Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71030

Vancouver

Weng D, Zhang P. Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71030

BibTeX
@article{Weng2026,
  author = {Weng, Dandan and Zhang, Pingping},
  title = {Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.71030}
}
Kostenlos starten →